Skip to main content

Jump to Section

MASSACHUSETTS ST DEV FIN AGY REV

CUSIP: 57584YQK8

By &Evergreen Team•Updated: Nov 18, 2025
BBB-Cautious

Overview

Overview
•Bond Name/Type: Massachusetts Development Finance Agency Revenue Bonds (Tufts Medicine / Wellforce Obligated Group, CUSIP 57584YQK8)
•Top-Line Classification: Cautious (medium confidence)
•Synopsis: FY 2024 CHIA filings show a –9.1 % operating margin, –0.94× DSCR and only 19.6 days-cash for the Obligated Group while long-term-debt equals roughly the mid-80s percent of capitalization (Signals 32, 31, 30, 23). Although YTD 6/30/25 losses have narrowed (–2.2 % margin), the Group is still burning equity in aggregate ((Massachusetts Center for Health Information and Analysis Hospital Financial Performance 2024 Databook; 2024-01-01)) and remains exposed to the 1.0× annual DSCR floor within the next 12 months, with the 2027 8.5 % bridge issue ((Massachusetts Center for Health Information and Analysis (CHIA) YTD Financial Data Through 6 30 2025; 2025-11-12)) sitting as a hard refinancing wall.

Rationale

Rationale
Wellforce experienced a severe financial crisis in FY 2022, posting a $250 million operating loss and –$204 million operating cash burn that drove system-wide days-cash from a historical 75+ days down to roughly 40 and forced total debt to about $992 million at 95 % of capitalization (Signals 32, 31, 30, 23, 29). In October 2024, constrained market access compelled the Obligated Group to issue a $150 million tax-exempt bridge at 8.5 % due October 2027—a rate signaling acute distress—to stabilize liquidity and fund ongoing operations ((Massachusetts Center for Health Information and Analysis (CHIA) YTD Financial Data Through 6 30 2025; 2025-11-12)). By FY 2024 (fiscal year ended Sept 30, 2024), losses had narrowed but the system remained in distress with a –9.1 % operating margin, –0.94× DSCR, and only 19.6 days-cash, effectively consistent with the covenant danger zone flagged in the master-indenture DSCR and days-cash tests (Signals 24, 30). The FY 2024 and YTD 6/30/25 improvements documented below represent a partial recovery from that crisis, but the Group remains sub-covenant on an economic basis, with continued equity erosion and a large bullet maturity within roughly 18–24 months (Signals 31, 23, 28).
Baseline from Foundation Analysis
•Structure: gross-receivables pledge; no rate-setting authority—operating risk stays with the Obligated Group.
•Covenant: minimum 1.0× DSCR is a performance floor under the Master Indenture.
•Historic cushion: >2.0× DSCR and >75 days cash, frequently supported by investment gains.
•Primary risks: margin volatility, thin liquidity versus fixed charges, above-market leverage.
Assessment of New Evidence (signals ordered by weight)
Liquidity & Cash Burn (Revenue | Liquidity)
•System days-cash effectively collapsed into the teens from the historic 75-day norm ((Massachusetts Center for Health Information and Analysis Hospital Financial Performance 2024 Databook; 2024-01-01)), with FY 2024 CHIA filings confirming ~19.6 days-cash and June-24 interim data showing an even lower intra-year point ((Wellforce Obligated Group FY2024 UGG Financials; 2024-09-30)).
•Unrestricted net assets continued to decline through 6/30/25, evidencing that the modest margin recovery has not yet translated to sustained cash generation and that the Obligated Group is still structurally cash-negative on a trailing basis ((Massachusetts Center for Health Information and Analysis Hospital Financial Performance 2024 Databook; 2024-01-01)). No structural mitigants exist under the gross-revenues pledge: any further operating slippage flows directly into covenant stress.
Leverage (Debt/Leverage)
•Debt-to-capitalization remains very high—mid-80s to mid-90s percent range depending on measure ((Massachusetts Center for Health Information and Analysis Databook Data Through June 30 2024; 2024-06-30))—materially above the ~60 % peer norm cited in the foundation and magnifying fixed-charge pressure as liquidity shrinks. The 8.5 % bridge financing, layered on top of existing long-term debt, keeps consolidated leverage elevated and compresses the margin for error ahead of the 2027 bullet (Signals 23, 29, 28).
Hospital-Level Traction but Uneven (Operations/Collections)
•Flagship Tufts MC rebounded from 2 days-cash and 0.65× DSCR at 6/30/24 ((Wellforce Obligated Group FY2024 UGG Financials; 2024-09-30)) to 20.7 days-cash and 1.36× DSCR at FY-end ((Massachusetts Center for Health Information and Analysis (CHIA) YTD Financial Report Through 12 31 2024; 2025-11-12)) and now posts a 2.3 % YTD margin with a $213 million equity gain ().
•Lowell General shows a similar upswing—YTD 6.0 % margin and $10 million equity add ((Massachusetts Center for Health Information and Analysis (CHIA) YTD Financial Data Through 6 30 2025; 2025-11-12))—but retains only 9 days-cash ((Massachusetts Center for Health Information and Analysis Annual Report Databook 2025; 2025-01-01)).
•Melrose-Wakefield remains liquidity-constrained (1.9 days-cash, 0.27× DSCR, (Massachusetts Center for Health Information and Analysis Annual Report Databook 2024; 2024-01-01)) despite edging into positive territory YTD 2025 ((Massachusetts Center for Health Information and Analysis (CHIA) YTD Financial Data Through 6 30 2025; 2025-11-12)).
•These improvements help, yet under a consolidated gross-receivables pledge the weakest link (Melrose-Wakefield) still drags on consolidated coverage and keeps economic DSCR near the 1.0× floor.
Red Flags
•Days-cash in the teens to low-20s across the Obligated Group (Signals 30, 27).
•Consolidated DSCR negative or near-zero on an economic basis in FY 2024 and still thin on a trailing basis despite hospital-level gains (Signals 32, 31).
•Leverage entrenched at the mid-80s to mid-90s percent of capitalization (Signals 23, 29).
Given that all three red flags hit foundation-identified primary risks and are not cushioned by structural protections, the Cautious classification remains appropriate.

Outlook

4. Outlook (12-month qualitative view)
Base Path: Modest operating gains continue but remain sub-breakeven, leaving DSCR near the 1.0× floor and days-cash hovering in the 20-30 range. Management’s FY 2025 budget and any external liquidity moves (summer 2025 board cycle) will be decisive.
Downside Scenario: If YTD improvements stall and net cash burn persists at FY 2024 levels, days-cash could slide below 15 and trigger a springing consultant or waiver request ahead of the next annual DSCR test (Signals 31, 32, 30).
Upside Scenario: Consolidated breakeven operations plus a material liquidity injection—through philanthropy, asset monetization or a system-wide cost reset—could rebuild days-cash above 45 and restore a 1.3×–1.5× DSCR, opening a path back to Stable.
Near-Term Catalysts
•FY 2025 Q2 results (April 2025) – first full quarter post-turnaround plan.
•Board decision on liquidity enhancement (summer 2025).
•Refinancing strategy for 2027 bullet maturities expected by year-end 2025.

Appendix

5. Appendix — Sources and Signals
•CHIA Hospital Financial Performance Databook; 2024-09-30
•Tufts Medicine Financial Report; 2024-06-30
•CHIA YTD Performance Databook; 2025-06-30
•Tufts Medical Center Financial Report; 2024-06-30
Data QA Notes
•CURRENT_RATING: “NR” – no agency rating conflicts.
•Interim CHIA YTD figures unaudited; margin calculations derive from CHIA tables, not issuer-filed statements.
•Foundation Analysis lacks explicit reserve-fund detail; assumes standard Massachusetts master-indenture construct.
Full Signal Details
(Verbatim text for Signals 22–33 and 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 retained in the underlying signal map.)

Related Signals

5 of 17

Related Bonds

View All →

PENNSYLVANIA ST HIGHER EDL FACS AUTH REV

70917TRY9
Revenue Bonds
Nov 1, 2054

PENNSYLVANIA ST HIGHER EDL FACS AUTH REV

70917TSA0
Revenue Bonds
Nov 1, 2054

PENNSYLVANIA ST HIGHER EDL FACS AUTH REV

70917TRM5
Revenue Bonds
Nov 1, 2038

Set up custom monitoring for your holdings

Get real-time alerts and deep credit analysis tailored to your portfolio

Get Started